The 4x upsizing of the ATM facility without a disclosed catalyst creates significant overhang. Traders should watch for actual ATM sales via daily volume patterns and any subsequent 8-K or prospectus supplement disclosing use of proceeds. The stock may trade under pressure as the market prices in potential dilution.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 12 $25.58entry
- T+1 · 3mo ago +0.27%α −0.42% · $25.65
- T+5 · 3mo ago −1.49%α −1.04% · $25.20
- T+20 · 2mo ago −8.64%α −6.74% · $23.37
- T+60 · 12d ago −9.38%α −4.51% · $23.18
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tango Therapeutics upsized its at-the-market (ATM) equity offering program from $100M to $400M, terminating the prior $100M facility under which $64.4M had already been sold. The new $400M shelf capacity represents a 4x increase in potential dilution, signaling aggressive capital raising for a biotech with a $4.0B market cap. This is a bearish signal as it dramatically expands the overhang of potential share issuance without any disclosed use of proceeds or operational catalyst to justify the dilution.
Key Facts
- Tango Therapeutics upsized its ATM offering from $100M to $400M in aggregate offering price.
- $64.4M of shares had already been sold under the prior $100M program.
- The prior $100M prospectus supplement has been terminated; the new $400M supplement includes the remaining $35.6M of unsold shares.
- The new shares are offered under the existing S-3ASR registration statement (File No. 333-291684) filed November 21, 2025.
- No specific use of proceeds or operational catalyst was disclosed to justify the 4x increase in potential dilution.
Financial Impact
Potential dilution of up to $400M in new common stock, representing ~10% of the $4.0B market cap if fully drawn; $64.4M already sold under prior facility.
Risk Factors
- Dilution risk from up to $400M in new shares being sold into the market.
- No disclosed use of proceeds creates uncertainty about capital allocation.
- ATM sales could pressure the stock price if executed aggressively.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-344997 |
| Document: d131656dex51.htm | 0001193125-26-344997 |
| Document: 0001193125-26-344997-index-headers.html | 0001193125-26-344997 |
| Document: 0001193125-26-344997-index.html | 0001193125-26-344997 |
| Document: 0001193125-26-344997.txt | 0001193125-26-344997 |
Track record
27 reports on TNGX
2 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +29.28% at T+60 after the Jun 8, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.22 Now $24.17 +0.21% settles Feb 16
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.50 Now $24.17 +1.35% settles Feb 12
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $22.74 Now $24.17 +6.29% settles Feb 5
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $21.50 Now $24.17 +12.42% settles Feb 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $20.87 Now $24.17 +15.81% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $23.34 Now $24.17 +3.56% settles Jan 21
- Aug 11, 202613w ago 8-K Bearish 6/10 Viewing Entry $25.58 to $23.18 Now $24.17 +5.51% ▲ +9.38% +4.51% vs SPY
- Aug 11, 202613w ago 8-K Bullish 7/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers